We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.
Oruka Therapeutics’ Post
More Relevant Posts
-
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 #stockmarket #stocks #investing #businessnews #trading #daytrading #earnings #financialresults
-
Managing Partner, CPA, CFA | SEC Compliance, IPO/SPAC Readiness | CFGI is a Carlyle and CVC Capital portfolio company
Insightful article on how CFGI supported Upstream Bio's $293 million IPO – a testament to strategic financial guidance and execution excellence - shout if you need help with your IPO readiness! https://lnkd.in/erQrz4Ec
-
As we enter the first quarter of 2025, explore what's driving the best #NASDAQ small-cap #biotechstocks by share price performance this past year. #NASDQstocks #bestperformingstocks #biotechstocks #biotechinvesting https://lnkd.in/gKc2G-c8
-
Arovella Therapeutics ASX: ALA announces a trading halt to prepare for a significant capital raise, raising investor anticipation. Read More https://lnkd.in/gegzhius #TradingHalt, #capitalRaise, #investment
-
-
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
🌡️ It's July and it's hot. And so is biotech: 💰 Two Massachusetts companies - #MassBioMember Scorpion Therapeutics and Cardurion Pharmaceuticals - just raised $410M in #oncology and #cardiovasculardisease respectively (Boston Business Journal: https://lnkd.in/eViMeruS). 📈 The $XBI is flirting on either side of $100 this week for the first time since March (Endpoints News: https://lnkd.in/ea4RXmy9). 💊 The drugs in these clinical trials (BioPharma Dive: https://lnkd.in/e_UpE-VM) and others could change lives. 📍And Worcester continues to make its strong case to be a #biomanufacturing hub (BBJ: https://lnkd.in/e-Z3hB6k). What's hot in your world?
-
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at HUJI
Small round but exclusive…
✨ We have closed the second and final tranche of our private placement, raising a total of $1.73M to accelerate our work in exosome-based therapies for CNS injuries. In addition, we’re excited to begin working with Independent Trading Group (ITG), Inc. and Oak Hill Financial Inc. to enhance our market presence and awareness! 🔍📈 https://lnkd.in/dwMrimxa
-
J&J $JNJ buys Intra-Cellular $ITCI in $14.6 billion deal, delving further into central nervous system disorders #Biotech #healthcare #mergers #acquisitions #JPM2025 #CNS #investing $IBB $XBI $SER $LTRN
-
Will Monte Rosa continue to dip in December?: Monte Rosa Therapeutics has $46.04 million in liabilities and a Debt to Equity (D/E) ratio of 0.16, indicating limited use of borrowing. With a current ratio of 19.71, the company is well-positioned to meet its financial obligations. When evaluating Monte Rosa's debt, it's important to consider its cash and equity positions. The company has a performance score of 11 out of 100 and a Beta of 5.01, suggesting high market risk. This means it could outperform in a rising market but may underperform if the market declines. To assess potential returns, consider using metrics like the Sortino ratio, skewness, period momentum indicator, and the relationship between potential upside and rate of daily change. Key Discoveries Monte Rosa Therapeutics' stock exhibits significant volatility, as highlighted by its Coefficient of Variation of 771.99, suggesting that price swings are substantial and could lead to unpredictable movements. With a Maximum Drawdown of 95.03, the stock has experienced severe declines, indicating that while a rebound is possible, investors should brace for potential further declines in December.Continue To Read... https://lnkd.in/gijkWP7p
Specialty Healthcare Sales
6moCongratulations!